Chronic exposure to glucocorticoids shapes gene expression and modulates innate and adaptive activation pathways in macrophages with distinct changes in leukocyte attraction

Journal of Immunology

Volumn 192, Issue 3, 2014, Pages 1196-1208

  Van De Garde, Martijn D B ^a   Martinez, Fernando O ^b   Melgert, Barbro N ^c,d   Hylkema, Machteld N ^d   Jonkers, René E ^a   Hamann, Jörg ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF GRONINGEN   (Netherlands)

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BUDESONIDE; FLUTICASONE PROPIONATE; GAMMA INTERFERON; GLUCOCORTICOID; LIPOPOLYSACCHARIDE; REGULATOR PROTEIN; TOLL LIKE RECEPTOR 4;

ADAPTIVE IMMUNITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; CELL MATURATION; CHEMOKINESIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DRUG EXPOSURE; GENE EXPRESSION; GENE IDENTIFICATION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; INNATE IMMUNITY; LEUKOCYTE ACTIVATION; MACROPHAGE ACTIVATION; MACROPHAGE FUNCTION; MALE; MOLECULAR MECHANICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATOR GENE; REGULATORY MECHANISM; TRANSCRIPTOMICS;

ADAPTIVE IMMUNITY; ANDROSTADIENES; ANIMALS; BUDESONIDE; CELLS, CULTURED; CYTOKINES; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORKS; HUMANS; IMMUNITY, INNATE; INTERFERON-GAMMA; LIPOPOLYSACCHARIDES; LUNG; MACROPHAGE ACTIVATION; MICE; MICE, INBRED C57BL; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RECEPTORS, GLUCOCORTICOID; SPECIFIC PATHOGEN-FREE ORGANISMS; TH1 CELLS; TOBACCO SMOKE POLLUTION; TOLL-LIKE RECEPTOR 4; TRANSCRIPTOME;

EID: 84893410522     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1302138     Document Type: Article

References (58)

1. Gordon, S., and P. R. Taylor. 2005. Monocyte and macrophage heterogeneity. Nat. Rev. Immunol. 5: 953-964.
2. Mosser, D. M., and J. P. Edwards. 2008. Exploring the full spectrum of macrophage activation. Nat. Rev. Immunol. 8: 958-969.
3. Sica, A., and A. Mantovani. 2012. Macrophage plasticity and polarization: in vivo veritas. J. Clin. Invest. 122: 787-795.
4. Murray, P. J., and T. A. Wynn. 2011. Protective and pathogenic functions of macrophage subsets. Nat. Rev. Immunol. 11: 723-737.
5. Glass, C. K., and K. Saijo. 2010. Nuclear receptor transrepression pathways that regulate inflammation in macrophages and T cells. Nat. Rev. Immunol. 10: 365-376.
6. Barnes, P. J. 2011. Glucocorticosteroids: current and future directions. Br. J. Pharmacol. 163: 29-43.
7. Esmailpour, N., P. Hogger, and P. Rohdewald. 1998. Binding kinetics of budesonide to the human glucocorticoid receptor. Eur. J. Pharm. Sci. 6: 219-223.
8. Yona, S., and S. Gordon. 2007. Inflammation: Glucocorticoids turn the monocyte switch. Immunol. Cell Biol. 85: 81-82.
9. Calverley, P. M., J. A. Anderson, B. Celli, G. T. Ferguson, C. Jenkins, P. W. Jones, J. C. Yates, and J. Vestbo; TORCH investigators. 2007. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N. Engl. J. Med. 356: 775-789.
10. Rabe, K. F., and J. A. Wedzicha. 2011. Controversies in treatment of chronic obstructive pulmonary disease. Lancet 378: 1038-1047.
11. Hakim, A., I. M. Adcock, and O. S. Usmani. 2012. Corticosteroid resistance and novel anti-inflammatory therapies in chronic obstructive pulmonary disease: current evidence and future direction. Drugs 72: 1299-1312.
12. Jen, R., S. I. Rennard, and D. D. Sin. 2012. Effects of inhaled corticosteroids on airway inflammation in chronic obstructive pulmonary disease: a systematic review and meta-Analysis. Int. J. Chron. Obstruct. Pulmon. Dis. 7: 587-595.
13. Baschant, U., N. E. Lane, and J. Tuckermann. 2012. The multiple facets of glucocorticoid action in rheumatoid arthritis. Nat. Rev. Rheumatol. 8: 645-655.
14. Gomes, J. A., R. D. Stevens, J. J. Lewin, III, M. A. Mirski, and A. Bhardwaj. 2005. Glucocorticoid therapy in neurologic critical care. Crit. Care Med. 33: 1214-1224.
15. Ciccone, A., S. Beretta, F. Brusaferri, I. Galea, A. Protti, and C. Spreafico. 2008. Corticosteroids for the long-term treatment in multiple sclerosis. Cochrane Database Syst. Rev. (1):CD006264.
16. Sorrells, S. F., J. R. Caso, C. D. Munhoz, and R. M. Sapolsky. 2009. The stressed CNS: when glucocorticoids aggravate inflammation. Neuron 64: 33-39.
17. Martinez, F. O. 2012. Analysis of gene expression and gene silencing in human macrophages. Curr. Protoc. Immunol. Chapter 14: Unit 23.
18. Martinez, F. O., L. Helming, R. Milde, A. Varin, B. N. Melgert, C. Draijer, B. Thomas, M. Fabbri, A. Crawshaw, L. P. Ho, et al. 2013. Genetic programs expressed in resting and IL-4 alternatively activated mouse and human macrophages: similarities and differences. Blood 121: e57-e69.
19. Ehrchen, J., L. Steinmuller, K. Barczyk, K. Tenbrock, W. Nacken, M. Eisenacher, U. Nordhues, C. Sorg, C. Sunderkotter, and J. Roth. 2007. Glucocorticoids induce differentiation of a specifically activated, anti-inflammatory subtype of human monocytes. Blood 109: 1265-1274.
20. van der Strate, B.W., D. S. Postma, C. A. Brandsma, B. N. Melgert, M. A. Luinge, M. Geerlings, M. N. Hylkema, A. van den Berg, W. Timens, and H. A. Kerstjens. 2006. Cigarette smoke-induced emphysema: A role for the B cell? Am. J. Respir. Crit. Care Med. 173: 751-758.
21. Melgert, B. N., W. Timens, H. A. Kerstjens, M. Geerlings, M. A. Luinge, J. P. Schouten, D. S. Postma, and M. N. Hylkema. 2007. Effects of 4 months of smoking in mice with ovalbumin-induced airway inflammation. Clin. Exp. Allergy 37: 1798-1808.
22. Griffith, R. B. 1984. A simple machine for smoke analytical studies and total particulate matter collection for biological studies. Toxicology 33: 33-41.
23. Griffith, R. B., and R. Hancock. 1985. Simultaneous mainstream-sidestream smoke exposure systems I. Equipment and procedures. Toxicology 34: 123-138.
24. Watson, E. S., A. B. Jones, M. K. Ashfaq, and J. T. Barrett. 1987. Spectrophotometric evaluation of carboxyhemoglobin in blood of mice after exposure to marijuana or tobacco smoke in a modified Walton horizontal smoke exposure machine. J. Anal. Toxicol. 11: 19-23.
25. Melgert, B. N., D. S. Postma, M. Geerlings, M. A. Luinge, P. A. Klok, B. W. van der Strate, H. A. Kerstjens, W. Timens, and M. N. Hylkema. 2004. Short-term smoke exposure attenuates ovalbumin-induced airway inflammation in allergic mice. Am. J. Respir. Cell Mol. Biol. 30: 880-885.
26. Liu, Y., Y. Endo, D. Iwaki, M. Nakata, M. Matsushita, I. Wada, K. Inoue, M. Munakata, and T. Fujita. 2005. Human M-ficolin is a secretory protein that activates the lectin complement pathway. J. Immunol. 175: 3150-3156.
27. Aho, S., P. Lehtinen, and E. Kulonen. 1980. Effects of purified macrophage RNase on granuloma fibroblasts with reference to silicosis. Acta Physiol. Scand. 109: 275-281.
28. Shaykhiev, R., A. Krause, J. Salit, Y. Strulovici-Barel, B. G. Harvey, T. P. O'Connor, and R. G. Crystal. 2009. Smoking-dependent reprogramming of alveolar macrophage polarization: implication for pathogenesis of chronic obstructive pulmonary disease. J. Immunol. 183: 2867-2883.
29. Sajjadi, F. G., K. Takabayashi, A. C. Foster, R. C. Domingo, and G. S. Firestein. 1996. Inhibition of TNF-Alpha expression by adenosine: role of A3 adenosine receptors. J. Immunol. 156: 3435-3442.
30. Haskó, G., C. Szabó, Z. H. Németh, V. Kvetan, S. M. Pastores, and E. S. Vizi. 1996. Adenosine receptor agonists differentially regulate IL-10, TNF-Alpha, and nitric oxide production in RAW 264.7 macrophages and in endotoxemic mice. J. Immunol. 157: 4634-4640.
31. Li, Q., P. W. Park, C. L. Wilson, and W. C. Parks. 2002. Matrilysin shedding of syndecan-1 regulates chemokine mobilization and transepithelial efflux of neutrophils in acute lung injury. Cell 111: 635-646.
32. Zahuczky, G., E. Kristof, G. Majai, and L. Fesu s. 2011. Differentiation and glucocorticoid regulated apopto-phagocytic gene expression patterns in human macrophages. Role of Mertk in enhanced phagocytosis. PLoS ONE 6: e21349.
33. Esmailpour, N., P. Hogger, K. F. Rabe, U. Heitmann, M. Nakashima, and P. Rohdewald. 1997. Distribution of inhaled fluticasone propionate between human lung tissue and serum in vivo. Eur. Respir. J. 10: 1496-1499.
34. Mukhopadhyay, S., L. Peiser, and S. Gordon. 2004. Activation of murine macrophages by Neisseria meningitidis and IFN-gamma in vitro: distinct roles of class A scavenger and Toll-like pattern recognition receptors in selective modulation of surface phenotype. J. Leukoc. Biol. 76: 577-584.
35. Schroder, K., K. M. Irvine, M. S. Taylor, N. J. Bokil, K. A. Le Cao, K. A. Masterman, L. I. Labzin, C. A. Semple, R. Kapetanovic, L. Fairbairn, et al. 2012. Conservation and divergence in Toll-like receptor 4-regulated gene expression in primary human versus mouse macrophages. Proc. Natl. Acad. Sci. USA 109: E944-E953.
36. Ogawa, S., J. Lozach, C. Benner, G. Pascual, R. K. Tangirala, S. Westin, A. Hoffmann, S. Subramaniam, M. David, M. G. Rosenfeld, and C. K. Glass. 2005. Molecular determinants of crosstalk between nuclear receptors and tolllike receptors. Cell 122: 707-721.
37. Lapperre, T. S., J. B. Snoeck-Stroband, M. M. Gosman, D. F. Jansen, A. van Schadewijk, H. A. Thiadens, J. M. Vonk, H. M. Boezen, N. H. Ten Hacken, J. K. Sont, et al; Groningen Leiden Universities Corticosteroids in Obstructive Lung Disease Study Group. 2009. Effect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease: a randomized trial. Ann. Intern. Med. 151: 517-527.
38. Thornton Snider, J., Y. Luna, K. S. Wong, J. Zhang, S. S. Chen, P. J. Gless, and D. P. Goldman. 2012. Inhaled corticosteroids and the risk of pneumonia in Medicare patients with COPD. Curr. Med. Res. Opin. 28: 1959-1967.
39. Sharif, O., U. Matt, S. Saluzzo, K. Lakovits, I. Haslinger, T. Furtner, B. Doninger, and S. Knapp. 2013. The scavenger receptor CD36 downmodulates the early inflammatory response while enhancing bacterial phagocytosis during pneumococcal pneumonia. J. Immunol. 190: 5640-5648.
40. Martinez, F. O., A. Sica, A. Mantovani, and M. Locati. 2008. Macrophage activation and polarization. Front. Biosci. 13: 453-461.
41. Koning, N., M. van Eijk, W. Pouwels, M. S. Brouwer, D. Voehringer, I. Huitinga, R. M. Hoek, G. Raes, and J. Hamann. 2010. Expression of the inhibitory CD200 receptor is associated with alternative macrophage activation. J. Innate Immun. 2: 195-200.
42. Ambarus, C. A., S. Krausz, M. van Eijk, J. Hamann, T. R. Radstake, K. A. Reedquist, P. P. Tak, and D. L. Baeten. 2012. Systematic validation of specific phenotypic markers for in vitro polarized human macrophages. J. Immunol. Methods 375: 196-206.
43. Petersen, H., A. Kullberg, S. Edsbacker, and L. Greiff. 2001. Nasal retention of budesonide and fluticasone in man: formation of airway mucosal budesonideesters in vivo. Br. J. Clin. Pharmacol. 51: 159-163.
44. Harrison, T. W., and A. E. Tattersfield. 2003. Plasma concentrations of fluticasone propionate and budesonide following inhalation from dry powder inhalers by healthy and asthmatic subjects. Thorax 58: 258-260.
45. Lacey, D. C., A. Achuthan, A. J. Fleetwood, H. Dinh, J. Roiniotis, G. M. Scholz, M. W. Chang, S. K. Beckman, A. D. Cook, and J. A. Hamilton. 2012. Defining GM-CSF-And macrophage-CSF-dependent macrophage responses by in vitro models. J. Immunol. 188: 5752-5765.
46. Sawmynaden, P., and M. Perretti. 2006. Glucocorticoid upregulation of the annexin-A1 receptor in leukocytes. Biochem. Biophys. Res. Commun. 349: 1351-1355.
47. Mozo, L., A. Suárez, and C. Gutiérrez. 2004. Glucocorticoids up-regulate constitutive interleukin-10 production by human monocytes. Clin. Exp. Allergy 34: 406-412.
48. Flammer, J. R., J. Dobrovolna, M. A. Kennedy, Y. Chinenov, C. K. Glass, L. B. Ivashkiv, and I. Rogatsky. 2010. The type I interferon signaling pathway is a target for glucocorticoid inhibition. Mol. Cell. Biol. 30: 4564-4574.
49. Snyder, D. S., and E. R. Unanue. 1982. Corticosteroids inhibit murine macrophage Ia expression and interleukin 1 production. J. Immunol. 129: 1803-1805.
50. Schwiebert, L. M., R. P. Schleimer, S. F. Radka, and S. J. Ono. 1995. Modulation of MHC class II expression in human cells by dexamethasone. Cell. Immunol. 165: 12-19.
51. Franchimont, D. 2004. Overview of the actions of glucocorticoids on the immune response: a good model to characterize new pathways of immunosuppression for new treatment strategies. Ann. N. Y. Acad. Sci. 1024: 124-137.
52. Warren, M. K., and S. N. Vogel. 1985. Opposing effects of glucocorticoids on interferon-gamma-induced murine macrophage Fc receptor and Ia antigen expression. J. Immunol. 134: 2462-2469.
53. Galon, J., D. Franchimont, N. Hiroi, G. Frey, A. Boettner, M. Ehrhart-Bornstein, J. J. O'Shea, G. P. Chrousos, and S. R. Bornstein. 2002. Gene profiling reveals unknown enhancing and suppressive actions of glucocorticoids on immune cells. FASEB J. 16: 61-71.
54. Viola, A., and A. D. Luster. 2008. Chemokines and their receptors: drug targets in immunity and inflammation. Annu. Rev. Pharmacol. Toxicol. 48: 171-197.
55. Kent, L. M., L. J. Smyth, J. Plumb, C. L. Clayton, S. M. Fox, D. W. Ray, S. N. Farrow, and D. Singh. 2009. Inhibition of lipopolysaccharide-stimulated chronic obstructive pulmonary disease macrophage inflammatory gene expression by dexamethasone and the p38 mitogen-Activated protein kinase inhibitor N-cyano-N'-(2-8-(2,6-difluorophenyl)-4-(4-fluoro-2-methylphenyl)-7-oxo-7, 8-dihydropyrido2,3-d pyrimidin-2-ylaminoethyl)guanidine (SB706504). J. Pharmacol. Exp. Ther. 328: 458-468.
56. Aoki, K., Y. Ishida, N. Kikuta, H. Kawai, M. Kuroiwa, and H. Sato. 2002. Role of CXC chemokines in the enhancement of LPS-induced neutrophil accumulation in the lung of mice by dexamethasone. Biochem. Biophys. Res. Commun. 294: 1101-1108.
57. Tagliabue, C., C. M. Salvatore, C. Techasaensiri, A. Mejias, J. P. Torres, K. Katz, A. M. Gomez, S. Esposito, N. Principi, and R. D. Hardy. 2008. The impact of steroids given with macrolide therapy on experimental Mycoplasma pneumoniae respiratory infection. J. Infect. Dis. 198: 1180-1188.
58. Wilckens, T., and R. De Rijk. 1997. Glucocorticoids and immune function: unknown dimensions and new frontiers. Immunol. Today 18: 418-424.